You are here

A new drug on the horizon?

Categories:


"Sun K706 is a novel tyrosine kinase inhibitor, intended for the treatment of chronic myelogenous leukemia (CML). While currently available oral drugs like Imatinib (Gleevec®), Nilotinib (Tasigna®) and Dasatinib (Spycel®) are quite effective chemotherapeutic agents for CML, these drugs are ineffective on the most resistant form of mutation in leukemic cells, viz. the T315I mutation. "

"Our novel NCE SUN-K706 targets this T315I resistance in CML. In vitro studies have demonstrated that SUN-K706 potently inhibits, besides other major mutant forms, the T315I mutant of the Abl kinase. Further, preclinical studies to demonstrate safety and efficacy are underway. "

Scuba,  Principal Investigator - Jorge Cortes :)

https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2016-0648.html

http://www.sunpharma.in/anti-cancer.htm

Hi Sandrea,

Yes this TKI is akin to ponatinib in that it targets the 'gate-keeper' multi-drug resistant mutation T315i. The number of patients who carry this mutation at diagnosis is very small, but it is good to know there is another TKI which targets this mutation on the horizon. There are currently 2 clinical trials open- both in the US, but there are clinical trials about to open  very soon here in Europe.

Sandy